Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
| Autor: | J M Dixon, Carole Farrell, Chris Plummer, Andrew Jones, Robert C. F. Leonard, A Stanley, Noreen E. Murray, Carlo Palmieri, Peter Barrett-Lee, Mark Verrill |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Heart Diseases Heart disease Anthracycline Breast Neoplasms Risk Assessment Breast cancer Risk Factors medicine Humans Anthracyclines Intensive care medicine Cardiotoxicity Antibiotics Antineoplastic Dose-Response Relationship Drug business.industry Patient Selection Cancer Hematology medicine.disease Surgery Oncology Heart failure Practice Guidelines as Topic Female Breast disease Drug Monitoring business |
| Zdroj: | Annals of Oncology. 20:816-827 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdn728 |
| Popis: | Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|